{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.696","value":"-88.25"},{"groupId":"OG001","spread":"122.735","value":"147.71"}]}],"title":"Week 1 Day 4 (Day 4)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.500","value":"-94.54"},{"groupId":"OG001","spread":"27.146","value":"-82.67"}]}],"title":"Week 5 Day 1 (Day 29)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.242","value":"-93.93"},{"groupId":"OG001","spread":"13.202","value":"-93.45"}]}],"title":"Week 25 Day 1 (Day 169)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.779","value":"-91.54"},{"groupId":"OG001","spread":"4.507","value":"-95.14"}]}],"title":"Week 49 Day 1 (Day 337)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"308"}],"units":"Participants"}],"description":"Blood samples were collected from participants for hormonal measurements.","dispersionType":"Standard Deviation","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"MEAN","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Week 1 Day 4 (Day 4), Week 5 Day 1 (Day 29), Week 25 Day 1 (Day 169), and Week 49 Day 1 (Day 337)","title":"Percent Change From Baseline In Serum Concentrations Of Luteinizing Hormone","type":"SECONDARY","unitOfMeasure":"Percent change"}